Literature DB >> 20023474

Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis.

Amisha V Barochia, Xizhong Cui, Charles Natanson, Peter Q Eichacker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20023474      PMCID： PMC3523296          DOI： 10.1097/CCM.0b013e3181b77fe3

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  18 in total

Review 1.  TLR4 antagonists for endotoxemia and beyond.

Authors:  Daniel P Rossignol; Melvyn Lynn
Journal:  Curr Opin Investig Drugs       Date:  2005-05

2.  The efficacy of drotrecogin alfa depends on severity of illness.

Authors:  Katherine J Deans; Peter C Minneci; Peter Q Eichacker; Charles Natanson
Journal:  Crit Care Med       Date:  2004-11       Impact factor: 7.598

3.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

4.  Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.

Authors:  Mark Tidswell; William Tillis; Steven P Larosa; Melvyn Lynn; Alec E Wittek; Richard Kao; Janice Wheeler; Jagadish Gogate; Steven M Opal
Journal:  Crit Care Med       Date:  2010-01       Impact factor: 7.598

5.  Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Authors:  Edward Abraham; Pierre-François Laterre; Rekha Garg; Howard Levy; Deepak Talwar; Benjamin L Trzaskoma; Bruno François; Jeffrey S Guy; Martina Brückmann; Alvaro Rea-Neto; Rolf Rossaint; Dominique Perrotin; Armin Sablotzki; Nancy Arkins; Barbara G Utterback; William L Macias
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

6.  Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.

Authors:  S Ridley; A Lwin; D Wyncoll; S Lippett; D Watson; K Gunning; D Higgins
Journal:  Eur J Anaesthesiol       Date:  2007-11-22       Impact factor: 4.330

Review 7.  Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review.

Authors:  Djillali Annane; Eric Bellissant; Pierre-Edouard Bollaert; Josef Briegel; Marco Confalonieri; Raffaele De Gaudio; Didier Keh; Yizhak Kupfer; Michael Oppert; G Umberto Meduri
Journal:  JAMA       Date:  2009-06-10       Impact factor: 56.272

8.  The effect of casemix adjustment on mortality as predicted by APACHE II.

Authors:  D R Goldhill; P S Withington
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

Review 9.  The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis.

Authors:  P C Minneci; K J Deans; P Q Eichacker; C Natanson
Journal:  Clin Microbiol Infect       Date:  2009-04       Impact factor: 8.067

10.  Drotrecogin alfa (activated): real-life use and outcomes for the UK.

Authors:  Kathryn M Rowan; Catherine A Welch; Emma North; David A Harrison
Journal:  Crit Care       Date:  2008-04-22       Impact factor: 9.097
View more
  4 in total

1.  Characterization of sparstolonin B, a Chinese herb-derived compound, as a selective Toll-like receptor antagonist with potent anti-inflammatory properties.

Authors:  Qiaoli Liang; Qinan Wu; Jihong Jiang; Jin'ao Duan; Chao Wang; Mark D Smith; Hong Lu; Qian Wang; Prakash Nagarkatti; Daping Fan
Journal:  J Biol Chem       Date:  2011-06-10       Impact factor: 5.157

2.  TLR4 inhibition impairs bacterial clearance in a therapeutic setting in murine abdominal sepsis.

Authors:  Miriam H P van Lieshout; Tom van der Poll; Cornelis van't Veer
Journal:  Inflamm Res       Date:  2014-08-15       Impact factor: 4.575

Review 3.  Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.

Authors:  Amisha Barochia; Steven Solomon; Xizhong Cui; Charles Natanson; Peter Q Eichacker
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-02-17       Impact factor: 4.481

4.  Danshen (Salvia miltiorrhiza) restricts MD2/TLR4-MyD88 complex formation and signalling in acute myocardial infarction-induced heart failure.

Authors:  Xiaoping Wang; Dongqing Guo; Weili Li; Qian Zhang; Yanyan Jiang; Qiyan Wang; Chun Li; Qi Qiu; Yong Wang
Journal:  J Cell Mol Med       Date:  2020-08-05       Impact factor: 5.310
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.